G1 Therapeutics to Share New Research Findings at AACR Annual Meeting 2014

Robust antitumor activity of G1's novel CDK4/6 inhibitors to be highlighted in poster on April 7

Mar 27, 2014, 09:00 ET from G1 Therapeutics, Inc.

CHAPEL HILL, N.C., March 27, 2014 /PRNewswire/ -- G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced that it will reveal new data on its novel, potent and selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors during a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014, to be held April 5-9 at the San Diego Convention Center in San Diego, CA. This will be the first public presentation of data on G1's CDK4/6 inhibitors.

Details of the presentation are as follows:

Abstract Number:  1322
Presentation Title:  Novel CDK4/6 inhibitors provide robust antitumor activity in a murine model of luminal breast cancer
Date:  Monday, April 7  
Time:  8 a.m.12 p.m. PDT
Location:  Hall A-E, Poster Section 14
Poster Board Number:  19    
Authors:   Patrick J. Roberts (1), David B. Darr (2), John E. Bisi (1), Jay C. Strum (1). (1) G1 Therapeutics, Inc, Chapel Hill, NC; (2) UNC Lineberger Comprehensive Cancer Center's Mouse Phase I Unit, Chapel Hill, NC  

For more information about the AACR Annual Meeting or to access abstracts, visit: http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2014.aspx.    

About G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a privately held pharmaceutical company based in Chapel Hill, NC that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications. These molecules are being developed for targeting specific proteins associated with cell proliferation and growth. Such therapies may be useful to protect the bone marrow and other organs, including the kidney and lung, from toxic insult. In October 2013, the company raised $12.5 million in a Series A financing led by MedImmune Ventures that will enable it to advance its lead clinical candidate into clinical trials for the potential treatment of chemotherapy induced myelosuppression. Visit www.g1therapeutics.com for more information.


SOURCE G1 Therapeutics, Inc.